Ovarian cancer screening and monitoring tests [For application of this section, see 84 Del. Laws, c. 488, § 3].
Del. Code tit. 29, § 5222
in effect(a) For purposes of this section:
(1) “At risk for ovarian cancer” means any of the following:
a. Having a family history of any of the following:
1. One or more first- or second-degree relatives with ovarian cancer.
2. Clusters of women relatives with breast cancer.
3. Nonpolyposis colorectal cancer.
4. Breast cancer in a male relative.
b. Testing positive for any of the following genetic mutations:
1. Brca1 or brca2.
2. Lynch Syndrome.
c. Having a personal history of any of the following:
1. Ovarian cancer.
2. Endometriosis.
3. Unexplained infertility.
4. Uterine fibroids.
5. Polycystic ovarian syndrome.
(2) “Monitoring tests” and “screening tests” mean tests and examinations for ovarian cancer using any of the following methods that are recommended by a patient’s physician:
a. Tumor marker tests supported by national clinical guidelines, national standards of care, or peer reviewed medical literature.
b. Transvaginal ultrasound.
c. Pelvic examination.
d. Other screening tests supported by national clinical guidelines, national standards of care, or peer reviewed medical literature.
(b) The plan shall provide coverage for all of the following:
(1) Monitoring tests for ovarian cancer after a woman is treated for ovarian cancer.
(2) Annual screening tests for women at risk for ovarian cancer.
(c) Coverage required by subsection (b) of this section must be at no cost to a covered individual, including deductible payments and cost-sharing amounts charged once a deductible is met.
Source: DE Code (Official Site)URL: https://delcode.delaware.gov/title29/c052/index.htmlFetched: 10/4/2026